The National Heart, Lung, and Blood Institute (NHLBI) awarded a $625,799 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. The grant, effective from Sep 1, 2024 to Jun 30, 2028, supports research to understand the role of cellular senescence in lung disease associated with Down syndrome. The project aims to explore the relationship between cellular senescence, interferon-I signaling, and Down syndrome, and evaluate the potential of senolytic and senomorphic therapies to treat lung disease in this population. The Lundquist Institute is collaborating with Mayo Clinic on this project, with Mayo Clinic responsible for studies using Down syndrome tissues and providing clinical and translational insights. This research seeks to advance the understanding of lung disease pathogenesis in Down syndrome and identify novel therapeutic approaches.
Generated 1/28/25, 9:34 AM